#USA #Milpitas #CE Mark #Galaxy Therapeutics #SEAL Embolization System

Galaxy Therapeutics Achieves CE Mark for SEAL™ Embolization System

In a significant advancement for medical technology, Galaxy Therapeutics has successfully secured CE Mark approval for its SEAL™ Embolization System. This marks a crucial step in the commercialization process, allowing the company to introduce its innovative solution for the treatment of intracranial aneurysms in Europe and beyond.

Based in Milpitas, California, Galaxy Therapeutics specializes in developing cutting-edge medical devices aimed at improving the outcomes of patients suffering from brain aneurysms. The SEAL™ Embolization System offers a unique intrasaccular approach designed specifically for the treatment of both ruptured and unruptured wide-neck aneurysms.

The CE Mark signifies that the SEAL Embolization System meets stringent European requirements for safety, quality, and clinical efficacy, as verified by the Notified Body DQS Medizinprodukte GmbH. This validation not only underscores the device's compliance with regulatory standards but also enhances its market availability across the European Economic Area.

Dr. Sam Zaidat, the President and CEO of Galaxy Therapeutics, expressed his enthusiasm regarding the CE Mark achievement, stating, "Receiving CE Mark represents one of the most significant milestones in Galaxy's history. This achievement reflects years of dedication from our entire team and validates the strength of the clinical evidence, engineering innovation, and quality systems behind SEAL. Most importantly, it allows us to bring this technology to physicians and patients across Europe who are seeking new treatment options for complex brain aneurysms."

The SEAL Embolization System has been developed through intensive collaboration among physicians, engineers, and clinical investigators, with its design aimed specifically at alleviating the challenges associated with treating intricate cases of intracranial aneurysms. Dr. Michael Alexander, Chief Medical Officer of Galaxy Therapeutics, articulated the device's advantages, stating that it broadens the range of treatment options available to medical professionals dealing with complex aneurysm sizes ranging from 2 to 19 mm, surpassing the capabilities of existing intrasaccular technologies.

The road to CE Mark approval for the SEAL system was paved with years of product development, engineering advancements, and clinical trials, including the pivotal SEAL IT IDE trial in the United States, which demonstrated remarkable patient enrollment rates.

Jim Twitchell, the Chief Operating Officer, highlighted the importance of teamwork in achieving CE certifications, noting, "Achieving CE certification required exceptional collaboration across every function of the company—from engineering and manufacturing to quality, regulatory, and clinical operations. This approval demonstrates the maturity of our organization and establishes the operational foundation needed to support commercial expansion throughout Europe and beyond."

Moving forward, Galaxy Therapeutics is committed to strategically introducing the SEAL Embolization System in chosen European markets and enhancing its clinical evidence base while progressing with regulatory initiatives, including the review of its Premarket Approval (PMA) application by the U.S. FDA.

As Galaxy prepares for the phased launch of the SEAL™ Embolization System, the company remains focused on collaborating with physicians around the globe to ensure that patients have access to this essential treatment option for complicated brain aneurysms. This launch signifies not just a regulatory success but also a transformative milestone for patients seeking advanced care in an often challenging medical area.

For more information about Galaxy Therapeutics and the SEAL Embolization System, visit Galaxy Therapeutics or follow them on LinkedIn.